Owing to
messenger RNA's unique biological advantages, it has received increasing attention to be used as a therapeutic, known as
mRNA-based gene therapy. It is critical to have an ideal strategy of
mRNA gene therapy for
glioma, which grows in a special environment. In the present study, we screened out a safe and efficient transfection
reagent for intracranial delivery of synthetic
mRNA in mouse brain. First, in order to analyze the effect of different transfection
reagents on the intracranial delivery of
mRNA, the synthetic
luciferase mRNA was wrapped with two different transfection
reagents and microinjected into the brain at the fixed point. The expression status of delivered
mRNA was monitored by a small animal imaging system. The possible
reagent-induced biological toxicity was evaluated by behavioral and blood biochemical measurements. Then, to test the
therapeutic effect of our intracranial delivery
mRNA model on
glioma, synthetic modified
tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL)
mRNA was used as an example of therapeutic application. This model demonstrated that synthetic
mRNA could be successfully delivered into the brain using commercially available transfection
reagents, and TransIT-
mRNA showed better results than in vivo-jetPEI kit. This model can be applied in precise targeting and personalized gene therapy of
glioma.